{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:07:28Z","timestamp":1776272848876,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"DOI":"10.7759\/cureus.94172","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:38:11Z","timestamp":1759999091000},"source":"Crossref","is-referenced-by-count":1,"title":["Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis"],"prefix":"10.7759","author":[{"given":"Vijay","family":"Lakshmanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield GM","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJ, et al.. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018, 67:1568-94. 10.1136\/gutjnl-2017-315259","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.03.025","article-title":"Global epidemiology of primary biliary cholangitis: an updated systematic review and meta-analysis","author":"Tan JJ","year":"2025","unstructured":"Tan JJ, Chung AH, Loo JH, et al.. Global epidemiology of primary biliary cholangitis: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025, 10.1016\/j.cgh.2025.03.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","unstructured":"UK-PBC. Epidemiology of PBC. (2025). Accessed: July 2025: https:\/\/www.uk-pbc.com\/about\/aboutpbc\/epidemiology-of-pbc\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","unstructured":"EASL clinical practice guidelines. the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017, 67:145-72. 10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"key":"ref5","unstructured":"National Institute for Health and Care Excellence. elafibranor for previously treated primary biliary cholangitis. (2024). Accessed: August 13, 2025: https:\/\/www.nice.org.uk\/guidance\/ta1016."},{"key":"ref6","unstructured":"Gov.UK. Seladelpar approved to treat adult patients in the UK with liver illness. (2025). Accessed: August 13, 2025: https:\/\/www.gov.uk\/government\/news\/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2023.22239","article-title":"Management of primary biliary cholangitis: current treatment and future perspectives","volume":"34","author":"Barba Bernal R","year":"2023","unstructured":"Barba Bernal R, Ferrigno B, Medina Morales E, et al.. Management of primary biliary cholangitis: current treatment and future perspectives. Turk J Gastroenterol. 2023, 34:89-100. 10.5152\/tjg.2023.22239","journal-title":"Turk J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al.. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016, 375:631-43. 10.1056\/NEJMoa1509840","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102464","article-title":"Obeticholic acid for primary biliary cholangitis","volume":"10","author":"Floreani A","year":"2022","unstructured":"Floreani A, Gabbia D, De Martin S. Obeticholic acid for primary biliary cholangitis. Biomedicines. 2022, 10:10.3390\/biomedicines10102464","journal-title":"Biomedicines"},{"key":"ref10","article-title":"Obeticholic acid","author":"Krupa KN","year":"2024","unstructured":"Krupa KN, Nguyen H, Parmar M. Obeticholic acid. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref11","article-title":"Appendix 5: summary of the long-term safety extension of the POISE trial","author":"Canadian Agency for Drugs and Technologies in Health","year":"2017","unstructured":"Canadian Agency for Drugs and Technologies in Health. Appendix 5: summary of the long-term safety extension of the POISE trial. Clinical Review Report: Obeticholic Acid (Ocaliva). Canadian Agency for Drugs and Technologies in Health, Ottawa (ON); 2017."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg JM","year":"2021","unstructured":"Schattenberg JM, Pares A, Kowdley KV, et al.. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021, 74:1344-54. 10.1016\/j.jhep.2021.01.013","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley KV","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al.. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024, 390:795-805. 10.1056\/NEJMoa2306185","journal-title":"N Engl J Med"},{"key":"ref14","article-title":"Elafibranor","year":"2024","unstructured":"Elafibranor. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2024."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield GM","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al.. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024, 390:783-94. 10.1056\/NEJMoa2312100","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25919","article-title":"Liver X receptor \u03b2 and peroxisome proliferator-activated receptor \u03b4 regulate cholesterol transport in murine cholangiocytes","volume":"56","author":"Xia X","year":"2012","unstructured":"Xia X, Jung D, Webb P, et al.. Liver X receptor \u03b2 and peroxisome proliferator-activated receptor \u03b4 regulate cholesterol transport in murine cholangiocytes. Hepatology. 2012, 56:2288-96. 10.1002\/hep.25919","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor \u03b4 agonist","volume":"109","author":"Iwaisako K","year":"2012","unstructured":"Iwaisako K, Haimerl M, Paik YH, et al.. Protection from liver fibrosis by a peroxisome proliferator-activated receptor \u03b4 agonist. Proc Natl Acad Sci U S A. 2012, 109:E1369-76. 10.1073\/pnas.1202464109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard JI","year":"2008","unstructured":"Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, et al.. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7:496-507. 10.1016\/j.cmet.2008.04.003","journal-title":"Cell Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones D","year":"2017","unstructured":"Jones D, Boudes PF, Swain MG, et al.. Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017, 2:716-26. 10.1016\/S2468-1253(17)30246-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer AE","year":"2024","unstructured":"Kremer AE, Mayo MJ, Hirschfield GM, et al.. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2024, 80:27-37. 10.1097\/HEP.0000000000000728","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.06.009","article-title":"Seladelpar as an alternate second-line agent for primary biliary cirrhosis","volume":"167","author":"Venkateswaran N","year":"2024","unstructured":"Venkateswaran N. Seladelpar as an alternate second-line agent for primary biliary cirrhosis. Gastroenterology. 2024, 167:1047. 10.1053\/j.gastro.2024.06.009","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince M","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002, 123:1044-51. 10.1053\/gast.2002.36027","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2015-100618","article-title":"A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis","volume":"7","author":"Hegade VS","year":"2016","unstructured":"Hegade VS, Bolier R, Oude Elferink RP, Beuers U, Kendrick S, Jones DE. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterol. 2016, 7:158-66. 10.1136\/flgastro-2015-100618","journal-title":"Frontline Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince MI","year":"2002","unstructured":"Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002, 50:436-9. 10.1136\/gut.50.3.436","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"Bergasa NV","year":"1992","unstructured":"Bergasa NV, Talbot TL, Alling DW, et al.. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992, 102:544-9. 10.1016\/0016-5085(92)90102-5","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcn043","article-title":"An integrated care pathway improves quality of life in primary biliary cirrhosis","volume":"101","author":"Jones DE","year":"2008","unstructured":"Jones DE, Sutcliffe K, Pairman J, Wilton K, Newton JL. An integrated care pathway improves quality of life in primary biliary cirrhosis. QJM. 2008, 101:535-43. 10.1093\/qjmed\/hcn043","journal-title":"QJM"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy C","year":"2023","unstructured":"Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023, 21:2076-87. 10.1016\/j.cgh.2023.02.005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi R","year":"2022","unstructured":"Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al.. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022, 76:75-85. 10.1016\/j.jhep.2021.08.025","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i7.107223","article-title":"Evolving therapeutic landscape of primary biliary cholangitis: a review","volume":"17","author":"Mitchell NE","year":"2025","unstructured":"Mitchell NE, Chan SY, Jerez Diaz D, Ansari N, Lee J, Twohig P. Evolving therapeutic landscape of primary biliary cholangitis: a review. World J Hepatol. 2025, 17:107223. 10.4254\/wjh.v17.i7.107223","journal-title":"World J Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00710-2","article-title":"Cholestatic itch: our current understanding of pathophysiology and treatments","volume":"23","author":"Vander Does A","year":"2022","unstructured":"Vander Does A, Levy C, Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. Am J Clin Dermatol. 2022, 23:647-59. 10.1007\/s40257-022-00710-2","journal-title":"Am J Clin Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389996-beyond-ursodeoxycholic-acid-a-comprehensive-review-of-second-line-agents-in-primary-biliary-cholangitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:38:17Z","timestamp":1759999097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389996-beyond-ursodeoxycholic-acid-a-comprehensive-review-of-second-line-agents-in-primary-biliary-cholangitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.94172","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}